SCHEMBL4599344

SCHEMBL4599344

Cc1cc(N)ccc1CNC(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4A O75164 1/20 0.44
▸ EPHX2 P34913 2/20 0.43
▸ NR1H4 Q96RI1 1/20 0.43
▸ IDO1 P14902 2/20 0.41
▸ BRD4 O60885 3/20 0.41
▸ KCNA5 P22460 1/20 0.40
▸ ADRB2 P07550 1/20 0.38
▸ ADRB1 P08588 1/20 0.38
▸ ADRB3 P13945 1/20 0.38
▸ NQO2 P16083 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ CA12 O43570 2/20 0.38
▸ CA1 P00915 2/20 0.38
▸ CA2 P00918 2/20 0.38
▸ CA9 Q16790 2/20 0.38
▸ HDAC1 Q13547 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL654820 0.90 KDM4A (0.45) KDM4AEPHX2NR1H4IDO1BRD4
SCHEMBL13385350 0.87 EPHX2 (0.47) KDM4AEPHX2NR1H4IDO1BRD4
SCHEMBL15171404 0.85 NPC1 (0.52) KDM4AEPHX2KCNA5L3MBTL1NPC1
SCHEMBL4597727 0.84 AKR1B1 (0.46) KDM4AEPHX2NR1H4IDO1BRD4
SCHEMBL4613309 0.84 EPHX2 (0.61) KDM4AEPHX2NR1H4IDO1KCNA5
SCHEMBL23762070 0.84 KCNA5 (0.46) KDM4AEPHX2NR1H4IDO1BRD4
SCHEMBL29350331 0.84 KDM4A (0.45) KDM4AEPHX2NR1H4IDO1BRD4
SCHEMBL12330489 0.84 KDM4A (0.45) KDM4AEPHX2NR1H4IDO1BRD4
SCHEMBL31129839 0.83 KLKB1 (0.46) KDM4AEPHX2L3MBTL1CA1CA2
SCHEMBL29955905 0.83 KDM4A (0.42) KDM4AEPHX2NR1H4IDO1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025049326-A1 TRICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 BIOCRYST PHARMACEUTICALS, INC. (US) 2025-03-06 — — WO disclosed
US-7456195-B2 Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-25 — — US disclosed
US-7456195-B2 Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-25 — — US disclosed
EP-1910298-A2 PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS Brystol-Myers Squibb Company (US) 2008-04-16 — — EP disclosed
WO-2007002313-A2 PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-04 — — WO disclosed
US-20070003539-A1 Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-04 — — US disclosed
US-20070003539-A1 Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070003539-A1 Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants F12, F11, F7 KDM4A 1398/4885EPHX2 1136/4885NR1H4 1443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback